Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Aging
Erschienen in: Drugs & Aging 10/2015

01.10.2015 | Review Article

Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin

verfasst von: Scott C. McFerren, Alex Gomelsky

Erschienen in: Drugs & Aging | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Overactive bladder (OAB) is a common constellation of lower urinary tract storage symptoms that causes a significant impact on a person’s quality of life. The elderly may be disproportionally impacted by these symptoms due to concomitant poor mobility, comorbid conditions such as diabetes and heart failure, and polypharmacy. While behavioral modification and pelvic floor muscle training should be considered first-line treatment options, pharmacotherapy remains the backbone of the therapeutic regimen. Trospium, oxybutynin, fesoterodine, and darifenacin all have unique properties that may confer certain advantages in the elderly population. The hydrophilicity and quaternary amine structure of trospium may limit its ability to cross the blood–brain barrier and thus minimize impact on cognition in the elderly. In its oral form, oxybutynin may have the most significant effect on cognition; however, the transdermal preparations may be favorable in the elderly population due to the ability to avoid first-pass metabolism and its limited antimuscarinic adverse effects. Fesoterodine may be the most extensively studied OAB medication in the elderly population. Darifenacin has a strong affinity for the M3 receptor in the bladder, while having a weak affinity for the M1 receptor commonly found in the brain. It must be noted that all muscarinic receptor antagonists are associated with common adverse effects to some degree, and frequent re-evaluation of the elderly patient is necessary to confirm the proper benefit-to-risk profile.
Literatur
1.
Abrams P, Andersson KE, Birder L, Members of Committees; Fourth International Consultation on Incontinence, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.CrossRefPubMed
2.
Stewart WF, van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMed
3.
4.
Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75:526–32.CrossRefPubMed
5.
Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. JMCP. 2014;20:130–40.PubMed
6.
Rodriguez LV, Blander DS, Dorey F, et al. Discrepancy in patient and physician perception of patient’s quality of life related to urinary symptoms. Urology. 2003;62:49–53.CrossRefPubMed
7.
Koyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95.CrossRef
8.
Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–107.PubMed
9.
Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S574–9.PubMed
10.
de Groat WC, Theobald RJ. Reflex activation of sympathetic pathways to vesical smooth muscle and parasympathetic ganglia by electrical stimulation of vesical afferents. J Physiol. 1976;259:223–37.PubMedCentralCrossRefPubMed
11.
12.
Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.CrossRefPubMed
13.
Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59:377–86.CrossRefPubMed
14.
Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129:416–9.PubMedCentralCrossRefPubMed
15.
Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–7.CrossRefPubMed
16.
Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes with ageing. Br J Pharmacol. 2005;144:1089–99.PubMedCentralCrossRefPubMed
17.
Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80:2303–7.CrossRefPubMed
18.
Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.PubMedCentralCrossRefPubMed
19.
Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23:248–52.CrossRefPubMed
20.
Chancellor MB, Staskin DR, Kay GG, Sandage BW Jr, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29:259–73.CrossRefPubMed
21.
Geyer J, Gavrilova O, Petzinger E. The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009;37:1371–4.CrossRefPubMed
22.
Geyer J, Gavrilova O, Schwantes U. Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin. UroToday Int J. 2010;3:1.CrossRef
23.
Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72:235–46.PubMedCentralCrossRefPubMed
24.
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150:1668–80.PubMed
25.
Lowalekar SK, Cristofaro V, Radisavljevic ZM, et al. Loss of bladder smooth muscle caveolae in the aging bladder. Neurourol Urodyn. 2012;31:586–92.CrossRefPubMed
26.
Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn 2010;29:408–12.
27.
Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22:1013–28.CrossRefPubMed
28.
Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99:502–9.CrossRefPubMed
29.
Kok ALM, Voorhorst FJ, Burger CW, et al. Urinary and faecal incontinence in community-residing older women. Age Ageing. 1992;21:211–5.CrossRefPubMed
30.
31.
DuBeau EC. Beyond the bladder: management of urinary incontinence in older women. Clin Obstet Gynecol. 2007;50:720–34.CrossRefPubMed
32.
Gomelsky A, Dmochowski RR. Urinary incontinence in the aging female: etiology, pathophysiology and treatment options. Aging Health. 2011;7:79–88.CrossRef
33.
Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17:947–63.CrossRefPubMed
34.
Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? J Am Geriatr Soc. 2004;52:2082–7.CrossRefPubMed
35.
Sink KM, Thomas J III, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56:847–53.CrossRefPubMed
36.
Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med. 2009;23:257–65.CrossRefPubMed
37.
Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.PubMed
38.
39.
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.CrossRefPubMed
40.
Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc. 2011;59:1477–83.CrossRefPubMed
41.
Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. American Urological Association; 2014.
42.
Frolich G, Bulitta M, Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. Int J Clin Pharmacol Ther. 2002;40:295–303.CrossRef
43.
Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171:2311–5.CrossRefPubMed
44.
Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67:275–80.CrossRefPubMed
45.
Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392–9.PubMed
46.
Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Sci. 2004;5:423–6.
47.
Diefenbach K, Arnold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int. 2005;95:346–9.CrossRefPubMed
48.
Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol. 2010;50:143–50.CrossRefPubMed
49.
Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009;63:1715–23.CrossRefPubMed
50.
Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011;30:1214–9.PubMed
51.
Sand PK, Johnson Ii TM, Rovner ES, et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥75 years) with overactive bladder syndrome. BJU Int. 2011;107:612–20.CrossRefPubMed
52.
Sanctura XR™ capsules [package insert]. East Brunswick, NJ: Esprit Pharmaceuticals., and Lexington, MA: Indevus Pharmaceuticals, Inc.; 2008.
53.
Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64:1294–300.CrossRefPubMed
54.
Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011;28:151–60.CrossRefPubMed
55.
Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract. 2010;64:1535–40.CrossRefPubMed
56.
Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1998;35:515–20.CrossRef
57.
Ditropan package insert (Marion Merrell Dow—U.S.); 1992.
58.
Buser N, Ivic S, Kesser TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–60.CrossRefPubMed
59.
Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62.CrossRefPubMed
60.
Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140:47–50.PubMed
61.
Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing. 1995;24:287–91.CrossRefPubMed
62.
Goode PS, Burgio KL, Locher JL, et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50:808–16.CrossRefPubMed
63.
Kennelly MJ. Oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010;12:12–9.PubMedCentralPubMed
64.
Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13.CrossRefPubMed
65.
66.
Ditropan XL package insert (Ortho-McNeil Pharmaceutical, Inc.); 1999.
67.
Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. 2000;85:793–8.CrossRefPubMed
68.
Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–64.CrossRefPubMed
69.
Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64:885–912.CrossRefPubMed
70.
Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin. 2012;28:1369–79.CrossRefPubMed
71.
Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50:317–26.CrossRefPubMed
72.
Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology. 2006;67:657–64.CrossRefPubMed
73.
Oxytrol [package insert]. Corona, California, Watson Pharma, Incorporated; 2003.
74.
Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Adult Urol. 2003;62:237–42.CrossRefPubMed
75.
Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicenter, community-based, randomized study. BJU Int. 2007;99:836–44.CrossRefPubMed
76.
Watson Pharmaceuticals, Inc. Gelnique® prescribing information. 2008.
77.
Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother. 2009;10:3103–11.CrossRefPubMed
78.
Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012;206:168.e1–6.
79.
Kay GG, Staskin DR, MacDiarmid S, et al. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clin Drug Investig. 2012;32:707–14.CrossRefPubMed
80.
Nilvebrant L, Hallen B, Larssen G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997;60:1129–36.CrossRefPubMed
81.
Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787–96.CrossRefPubMed
82.
Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204–12.CrossRefPubMed
83.
Nitti VW, Dmochowski RR, Sand PK, et al. Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178:2488–94.CrossRefPubMed
84.
Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population. J Am Geriatr Soc. 2013;61:185–93.CrossRefPubMed
85.
Wagg A, Khullar V, Michel MC, Oelke M, Darekar A, Bitoun CE. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodynam. 2014;33:106–14.CrossRef
86.
DuBeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled Trial. J Urol. 2014;191:395–404.CrossRefPubMed
87.
Natalin R, Lorenzetti F, Dambros M. Management of OAB in those over age 65. Curr Urol Rep. 2013;14:379–85.CrossRefPubMed
88.
Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. Clin Interv Aging. 2008;3:503–9.PubMedCentralPubMed
89.
Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2004;95:993–1001.CrossRef
90.
Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23:2347–58.CrossRefPubMed
91.
Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62:1792–800.PubMedCentralCrossRefPubMed
92.
Kay GG, Wesnes K. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of over- active bladder, in healthy volunteers. BJU Int. 2005;96:1055–62.CrossRefPubMed
93.
Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173:493–8.CrossRefPubMed
94.
Tack J, Wyndaele JJ, Ligozio G, Egermark M. A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. Drug Healthc Patient Saf. 2012;4:127–39.PubMedCentralCrossRefPubMed
95.
Olshanky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther. 2008;13:241–51.CrossRef
96.
Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin. 2007;23:2697–704.CrossRefPubMed
Metadaten
Titel
Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin
verfasst von
Scott C. McFerren
Alex Gomelsky
Publikationsdatum
01.10.2015
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 10/2015
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0301-x

Weitere Artikel der Ausgabe 10/2015

Drugs & Aging 10/2015 Zur Ausgabe

Review Article

Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients

Original Research Article

Prevalence of Potential and Clinically Relevant Statin–Drug Interactions in Frail and Robust Older Inpatients

Review Article

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

Leading Article

Pharmacotherapy to Enhance Cognitive and Motor Recovery Following Stroke

Review Article

Tolerability of Antihypertensive Medications in Older Adults

Letter to the Editor

Author’s Reply to Zekry and Inderjeeth: “Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?”

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise